Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from LLY

3 Growth Stocks to Buy if You Think Inflation Has Peaked

A slightly lower consumer price index in April and expectations of a flat or lower CPI in May indicate inflation may have peaked. Yesterday, the major U.S. stock indices increased slightly as leading growth stocks rallied. Given this backdrop, we think it could be wise to invest in the shares…

StockNews.com

In Eli Lilly's Lebrikizumab Atopic Dermatitis Study, Majority Of Patients Maintained Skin Clearance At One Year

Eli Lilly And Co (NYSE:LLY) announced topline results from one-year analyses of the efficacy and safety of lebrikizumab for moderate-to-severe atopic dermatitis (AD). The new findings from the Phase 3 trials (ADvocate 1 and 2) showed that 8/10 of patients who achieved clinical response with lebrikizumab monotherapy at 16 weeks maintained skin clearance…

Benzinga

Eli Lilly Presents New Analyses On Tirzepatide Injection For Type 2 Diabetes

Eli Lilly And Co (NYSE:LLY) presented new data from a mechanism of action study and new analyses of the global registration program for Mounjaro (tirzepatide) injection at the American Diabetes Association. At 28 weeks, participants taking Mounjaro (N=45) had significantly greater reductions in weight and fat mass compared to Novo Nordisk A/S's (NYSE:NVO) injectable Ozempic…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Flirts With Buy Point On A 'Flawless' Update For Its Diabetes-Turned-Obesity Drug

Eli Lilly delivered a promising update for its experimental obesity treatment over the weekend, leading LLY stock to pop Monday.

Investors Business Daily

Northrop Grumman, Eli Lilly Lead 5 Stocks Near Buy Points Geared For This Economy

Eli Lilly and Northrop Grumman lead five stocks near buy points that are solid bets to withstand the coming Federal Reserve-induced slowdown.

Investors Business Daily

Looking At Eli Lilly's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Stock Market Closes Sharply Higher As Key Inflation Rate Lower Than Expected; Tesla, Boeing, Apple Lead Indexes

The stock market extended its rally to a third day as a key inflation rate came in lower than expected. Tesla, Apple, Boeing led.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Why Leaderboard And IBD 50 Stock Eli Lilly Just Became Actionable

Eli Lilly said Friday it will unveil new test results for its biggest cancer drug, Verzenio, in June and LLY stock broke out to a fresh high.

Investors Business Daily

Lilly Touts Encouraging Mirikizumab Data In Ulcerative Colitis Maintenance Setting

Eli Lilly And Co (NYSE:LLY) announced a data readout for the Lucent-2 Phase 3 study of mirikizumab after 52 weeks. The trial enrolled patients with ulcerative colitis who had initially responded to mirikizumab in a 12-week Lucent-1 study. The primary endpoint was clinical remission, with 49.9% of participants in the mirikizumab arm reaching…

Benzinga

Dow Jones Futures Rise After 'Hard' Reality Hits Market; What To Do Now

Dow Jones futures rose, but be wary after the stock market suffered another week of solid losses as fears grew of a "hard" economic landing.

Investors Business Daily

CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) for severe alopecia areata (AA). If approved, Olumiant would be the first centrally-authorized oral treatment and first JAK inhibitor for severe AA in the European Union. …

Benzinga

Dow Jones Futures Fall As Target Crashes On Earnings Miss; Now What For Market Rally?

Futures fell as Target dived early on a big profit miss. The stock market rally had a strong Tuesday. Broadcom looked actionable.

Investors Business Daily

Top-Rated Eli Lilly Nears Breakout After FDA Approves Its Next Potential Blockbuster

The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout.

Investors Business Daily

Why Eli Lilly Shares Are Trading Higher Today

The FDA approved Eli Lilly And Co's (NYSE:LLY) injected drug tirzepatide, which has the brand name Mounjaro (tirzepatide), to help improve blood sugar control in adults with type 2 diabetes. The approval covers tirzepatide as an adjunct to diet and exercise. As the first and only FDA-approved GIP (glucose-dependent insulinotropic polypeptide) and GLP-1…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly, Albemarle Lead Five Ways To Play A Stock Market Rally

Eli Lilly and Albemarle lead five stocks that have shown resilience amid the sell-off and may be poised to lead the way forward.

Investors Business Daily

Dow Jones Futures Extend Stock Market Sell-Off; This Should Worry Investors

The stock market tumbled Wednesday on a hot inflation report. A lack of investor fear suggests no market bottom yet.

Investors Business Daily

IBD Stock Of The Day Eli Lilly Is Eyeing Not One — But Two — Multibillion-Dollar Opportunities

Eli Lilly is the IBD Stock Of The Day after "transformative" data in obesity helped LLY stock retain its recent breakout.

Benzinga

Eli Lilly's Olumiant Becomes First FDA Approved Immunomodulatory Treatment For COVID-19

The FDA approved Eli Lilly And Co's (NYSE:LLY) Olumiant (baricitinib) for COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Olumiant is the first immunomodulatory treatment for COVID-19 to receive FDA approval. The FDA first issued an emergency use authorization (EUA) for Olumiant combined with remdesivir to treat…

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Tumble As Market Correction Extends Losses; Why Apple Is An 'Absolute Loser'

The market correction suffered a violent sell-off late in the week. Apple is a relative winner but an absolute loser.

Investors Business Daily

IBD 50 Stocks To Watch: Medical Stock Eli Lilly Trades In Buy Zone After Reporting Promising Q1 Results

With several core products showing strength, along with their Covid-19 antibodies, Eli Lilly updated their 2022 EPS guidance.

Benzinga

Here's How Much $1000 Invested In Eli Lilly 10 Years Ago Would Be Worth Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 9.8% on an annualized basis producing an average annual return of 21.54%. Currently, Eli Lilly has a market capitalization of $276.68 billion.

Investors Business Daily

Dow Jones Falls, Nasdaq Skids On Amazon, AbbVie; Tesla Rises On Elon Musk Move

Stocks fell Friday as Amazon and AbbVie tumbled on earnings. Elon Musk disclosed Tesla stock sales.

Benzinga

Eli Lilly Whale Trades For April 28

Benzinga's options scanner just detected over 16 options trades for Eli Lilly (NYSE:LLY) summing a total amount of $701,114. At the same time, our algo caught 4 for a total amount of 146,845.

Benzinga

Lilly's Tirzepatide Shows Up To 22.5% Weight Loss In New Phase 3 Readout

Eli Lilly And Co (NYSE:LLY) reported topline results from SURMOUNT-1 Phase 3 trial evaluating Tirzepatide (5 mg, 10 mg, 15 mg) in obese patients with at least one comorbidity who do not have diabetes. Data exhibited that tirzepatide reduced patients' weights by an average of 16%, 21.4%, and 22.5% at the respective doses,…

Benzinga

Eli Lilly Achieves 80% Jump In COVID-19 Therapy Sales, Revises FY22 Guidance

Eli Lilly And Co (NYSE:LLY) has posted Q1 sales of $7.8 billion, beating the consensus of $6.68 billion. Lilly's revenue increased 15%, driven by volume growth of 20%, partially offset by a 3% decrease due to lower realized prices and a 2% decrease due to the unfavorable impact of foreign exchange rates. …

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.